[The new guideline on irritable bowel syndrome: what is new?]

Abstract

IRRITABLE BOWEL SYNDROME:

WHAT IS NEW?:  The following refers only to irritable bowel syndrome (IBS) in adults. The new guideline includes a separate section on IBS for paediatric patients. Irritable bowel syndrome (IBS) presents as a heterogeneous picture with chronic abdominal complaints related to the bowel. These are usually accompanied by changes in bowel movements and lead to impaired quality of life. The genesis is multifactorial and there are complex underlying pathophysiological mechanisms associated with IBS. Thus, disturbances in various components of the gut-brain axis and the increasing importance of the microbiome can be identified. Various psychological comorbidities also play a role.

DIAGNOSTICS:

The diagnosis is made by a thorough anamnesis and symptom-oriented exclusion of important differential diagnoses. A subdivision into different subtypes depending on the main symptoms is beneficial for the further management of IBS patients. The diagnosis of IBS should be made as early as possible after reliable exclusion of the important differential diagnoses. If diarrhoea dominates as a symptom, a detailed differential diagnosis and functional diagnosis should be carried out.

THERAPY:

There is no proven causal and no established standard therapy. Due to the variable genesis and symptom manifestation of IBS, a broad spectrum of therapy options results, whereby there is no individual prediction regarding effectiveness and therefore every therapy is initially probationary. Symptom-independent general therapies that can be used for all subtypes include dietary methods (e. g. the low-FODMAP diet), probiotics, psychotherapy methods and complementary medicine. The choice of symptom-dependent drug treatments is made according to the subtype/main symptom. In the case of diarrhoea, bile acid binders, the non-absorbable antibiotic rifaximin or, in individual cases, 5-HT3-antagonists can be used in addition to loperamide. In constipation, prucalopride and linaclotide have value in addition to the use of soluble fibre and macrogol/other laxatives. For abdominal pain/cramps, studies show good results for spasmolytics, especially peppermint oil, and for tricyclic-type antidepressants. For the main symptom of flatulence, probiotics, rifaximin and especially the low-FODMAP diet can show positive results in studies.

• Authors: Henrike von Schassen, Viola Andresen, Peter Layer
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 146 Issue 19 Pg. 1243-1248 (10 2021) ISSN: 1439-4413 [Electronic] Germany
• Vernacular Title: Die neue Leitlinie zum Reizdarmsyndrom: Was ändert sich?
• PMID: 34553347 (Publication Type: Journal Article)
• Copyright: Thieme. All rights reserved.

Topics

• Brain-Gut Axis (physiology)
• Constipation
• Diarrhea
• Humans
• Irritable Bowel Syndrome (physiopathology, psychology, therapy)
• Practice Guidelines as Topic
• Probiotics
• Quality of Life